Simple Summary According to the 2020 World Health Organization classification, a giant cell
tumor of bone is an intermediate malignant bone tumor. Denosumab treatment before …

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor
of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is …

Primary bone tumours are rare, accounting for< 0.2% of malignant neoplasms registered in
the EUROCARE (European Cancer Registry based study on survival and care of cancer …

For the related but heterogenous group of giant cell rich tumors of bone, like aneurysmal
bone cysts (ABC) and central giant cell granuloma (CGCG), denosumab is a new treatment …

The molecular triad involving receptor activator of nuclear factor kβ (RANK)/RANK ligand
(RANKL)/osteoprotegerin cytokine system has been well implicated in several physiological …

Background Denosumab, a monoclonal antibody that binds to receptor activation of nuclear
factor-kappa ß ligand (RANKL), has been used as a drug to treat aggressive giant cell …

Simple Summary The widely accepted local therapy in extremity giant cell tumor of bone
(GCTB) is surgery, in the form of extended intralesional curettage with adequate disease …

Bone sarcoma are infrequent diseases, representing< 0.2% of all adult neoplasms. A
multidisciplinary management within reference centers for sarcoma, with discussion of the …

Aims Local recurrence remains a challenging and common problem following curettage and
joint-sparing surgery for giant cell tumour of bone (GCTB). We previously reported a 15 …

Aims Denosumab, a human monoclonal antibody directed against the receptor activator of
nuclear factor‐κB ligand (RANKL), is a therapeutic agent for giant cell tumour of bone …